Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04613596
Title Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mirati Therapeutics Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUT | AUS


No variant requirements are available.